Macrophage Polarization during MRONJ Development in Mice.

bone biology immunity inflammation osteonecrosis periodontal disease(s)/periodontitis periodontal tissues/periodontium

Journal

Journal of dental research
ISSN: 1544-0591
Titre abrégé: J Dent Res
Pays: United States
ID NLM: 0354343

Informations de publication

Date de publication:
05 Aug 2024
Historique:
medline: 6 8 2024
pubmed: 6 8 2024
entrez: 6 8 2024
Statut: aheadofprint

Résumé

Macrophages are important regulators of bone remodeling, and M1 polarization is observed in the setting of medication-related osteonecrosis of the jaws (MRONJ). Here, we characterize the phenotype of macrophages during early stages of MRONJ development in zoledronate (ZA)-treated mice with periodontal disease and explore the role of rosiglitazone, a drug that has been reported to lower the M1/M2 macrophage ratio, in MRONJ burden. Mice received ZA, and experimental periodontal disease (EPD) was induced around their second left maxillary molar. The mice were euthanized 1, 2, or 4 wk later. Micro-computed tomography and histologic and immunohistochemical analyses were carried out. In a separate experiment, mice were treated with ZA in the absence or presence of rosiglitazone, EPD was induced for 5 wk, and the MRONJ burden was assessed. An M1 predilection was noted in ZA versus vehicle (Veh) mice at 1, 2, or 4 wk after ligature placement. M1 cells were found to be positive for MMP-13, and their presence coincided with disruption of the surrounding collagen network in ZA mice. Rosiglitazone caused a reversal in the M1/M2 polarization in Veh and ZA mice. Rosiglitazone did not cause significant radiographic changes 5 wk after EPD in Veh or ZA animals. Importantly, percentage osteonecrosis and bone exposure were decreased in the rosiglitazone-treated versus nontreated ZA sites 5 wk after EPD. Our data point to an important role of M1 macrophage polarization with an overexpression of MMP-13 in the early phases of MRONJ development and provide insight into the use of interventional approaches promoting an M2 phenotype as a preventative means to alleviate MRONJ burden.

Identifiants

pubmed: 39104155
doi: 10.1177/00220345241258990
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

220345241258990

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

A Soundia (A)

Private practice, Kennewick, WA, USA.

N Elzakra (N)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

D Hadaya (D)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

I Gkouveris (I)

Private practice, Piraeus, Athens, Greece.

O Bezouglaia (O)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

S Dry (S)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

T Aghaloo (T)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

S Tetradis (S)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

Classifications MeSH